Saturday 17 October 2026
Export INAB’s income statement to Excel — free account
IN8bio, Inc.
INAB Healthcare Biotechnology
In the quarter to June 2026, EPS grew 79.8% and free cash flow fell 1.30%, each against the same quarter a year earlier.
1.11
0.08
−6.72%
Follow INAB
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 128.40 | 41.40 | 19.50 | 6.51 | 1.17 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 309.57 | 149.40 | 118.50 | 57.90 | 12.54 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 7 | 13 | 19 | 26 | 31 | 18 | 17 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | (2) | (5) | (9) | (15) | (29) | (30) | (30) | (19) | |||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | (2) | (5) | (9) | (15) | (29) | (30) | (30) | (19) | |||||
| Depreciation | — | — | 0 | 0 | 0 | 1 | 1 | 3 | 3 | 3 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | (0.13) | (48.36) | (15.04) | (44.14) | (40.84) | (30.03) | (17.12) | (4.44) | |||||
| Cash flow | — | — | (0.14) | (45.21) | (62.63) | (40.69) | (34.55) | (23.47) | (13.53) | (2.91) | |||||
| Capex | — | — | 0.00 | 3.35 | 0.00 | (0.93) | (5.31) | (0.60) | (0.10) | 0.00 | |||||
| Free cash flow | — | — | (0.14) | (41.85) | (62.63) | (41.62) | (39.85) | (24.07) | (13.63) | (2.91) | |||||
| Book value | — | — | 0.24 | (3.26) | 160.85 | 115.01 | 32.56 | 25.07 | 8.11 | 6.30 | |||||
| Shares, m | — | — | 19 | 0 | 0 | 0 | 1 | 1 | 2 | 4 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (3) | (5) | (7) | (14) | (24) | (23) | (24) | (13) | ||||
| Capex | — | — | (1) | 0 | — | 0 | (4) | (1) | 0 | — | |||||
| Free cash flow | — | — | (3) | (4) | (7) | (14) | (28) | (24) | (24) | (13) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | 5 | 0 | 16 | 37 | 16 | 19 | 9 | 25 | ||||
| Total debt | — | — | — | — | 0 | 0 | 1 | 1 | 0 | — | |||||
| Net debt | — | — | (5) | (1) | (18) | (37) | (17) | (21) | (11) | (27) | |||||
| Shareholders’ equity | — | — | 5 | 0 | 18 | 38 | 23 | 25 | 14 | 28 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | (85.12) | (168.31) | (93.83) | (46.42) | (75.79) | (89.91) | (111.38) | (73.05) | ||||
| ROIC | — | — | 0.00 | 0.00 | (1,067.49) | (639.98) | (332.51) | (453.60) | (524.69) | (2,663.76) | |||||
| ROE | — | — | 37.20 | 87.64 | 80.09 | (135.65) | (93.64) | (125.90) | (154.44) | (92.49) | |||||
Negative figures in brackets.
Charts ten years each
IN8bio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| AEON AEON Biopharma, Inc. | $12.1M | — (loss-making) | — | — | n/m | −76.85% (below 0%: shrinking) | — | 0.00% | Compare |
| ASBP Aspire-Lakewood Holdings, Inc. | $12.1M | 0.2× | — | — | n/m | −85.54% (below 0%: shrinking) | (47.70%) | (4,244.37%) | Compare |
| ACTU Actuate Therapeutics, Inc. | $12.0M | — (loss-making) | — | — | n/m | −5.54% (below 0%: shrinking) | — | 0.00% | Compare |
| PLUR Pluri Inc. | $11.9M | — (loss-making) | — (loss-making) | −15.83% (below 0%: shrinking) | n/m | +25.03% (above 0%: growing) | 58.51% | (1,655.52%) | Compare |
| INAB IN8bio, Inc. | $11.7M | — (loss-making) | — | — | n/m | −1.30% (below 0%: shrinking) | 0.00% | 0.00% | |
| ENSC Ensysce Biosciences, Inc. | $11.6M | — (loss-making) | — (loss-making) | −15.10% (below 0%: shrinking) | n/m | +27.50% (above 0%: growing) | 100.00% | (221.28%) | Compare |
| PASG Passage Bio, Inc. | $11.6M | — (loss-making) | — | — | n/m | −59.81% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PTN Palatin Technologies, Inc. | $11.6M | — (loss-making) | 0.2× | −14.06% (below 0%: shrinking) | n/m | +34.21% (above 0%: growing) | 100.00% | (1,469.35%) | Compare |
| CLRB Cellectar Biosciences, Inc. | $11.2M | — (loss-making) | — | −73.23% (below 0%: shrinking) | n/m | −17.49% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $11.8M | — | — | −15.46% | — | −11.51% | 29.26% | (110.64%) |
IN8bio, Inc. (INAB) key facts
- IN8bio, Inc. (INAB) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, INAB traded at $1.11, a market capitalization of $11.7 million.
- Return on equity was −92.5% and debt-to-equity 0.00.